PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis

BackgroundInhibitors of programmed cell death 1 (PD-1)/programmed cell death ligand 1(PD-L1) checkpoint have been approved for metastatic triple negative breast cancer (mTNBC) in patients positive for PD-L1 expression. Negative results from the recent phase III trials (IMPassion131 and IMPassion132)...

Full description

Bibliographic Details
Main Authors: Muhammad Khan, Kunpeng Du, Meiling Ai, Baiyao Wang, Jie Lin, Anbang Ren, Chengcong Chen, Zhong Huang, Wenze Qiu, Yawei Yuan, Yunhong Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
breast cancer
immunotherapy
immune checkpoint inhibitors (ICI)
pembrolizumab
atezolizumab
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1060308/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1060308/full

Similar Items